Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis
1 other identifier
observational
207
1 country
1
Brief Summary
This study objective is to compare the high sensitive troponin-I level in end-stage renal disease patients received hemodialysis without acute cardiovascular event with healthy population. The investigators also determine the effect of hemodialysis on troponin I level as the secondary objective.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2015
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
October 7, 2015
CompletedFirst Posted
Study publicly available on registry
October 9, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2015
CompletedJanuary 29, 2016
January 1, 2016
9 months
October 7, 2015
January 27, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
High Sensitive Troponin-I in ESRD group vs Control group
ESRD group * Measure the High Sensitive Troponin-I level before the hemodialysis session Control group * Measure the High Sensitive Troponin-I as an additional test to their follow up blood check.
10 months
Secondary Outcomes (1)
High Sensitive Troponin-I in pre-hemodialysis vs post-hemodialysis
4 hours
Study Arms (2)
ESRD group
1. Aged 18 years or older. 2. was diagnosed as End-stage renal disease for more than one year. 3. Attend hemodialysis 3 times a week consistently for more than 6 months. 4. Hemodialysis with Kt/V \> 1.2 5. No urine output or is less than 500 ml per day. 6. No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks.
Control group
1. Aged 18 years or older. 2. without kidney disease (eGFR \> 60 ml/min/1.73m2)
Interventions
Eligibility Criteria
ESRD group End-stage renal disease patients receiving regular hemodialysis at King Chulalongkorn memorial hospital, Bhumirajanagarindra kidney institute hospital. Control group Patients who come to OPD at King Chulalongkorn memorial hospital for their follow up blood check.
You may qualify if:
- Aged 18 years or more.
- was diagnosed as End-stage renal disease for more than one year.
- Attend hemodialysis 3 times a week consistently for more than 6 months.
- Hemodialysis with Kt/V \> 1.2
- No urine output or is less than 500 ml per day.
- No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks.
You may not qualify if:
- Could not complete hemodialysis, or Kt / V \<1.2
- Has symptoms of myocardial infarction while receiving dialysis
- Has the abnormal symptom (fever, chill, low BP) While receiving dialys
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Chulalongkorn Memorial Hospital
Bangkok, Bangkok, 10330, Thailand
Biospecimen
blood sample
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Khajohn Tiranathanagul, MD
Chulalongkorn University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
October 7, 2015
First Posted
October 9, 2015
Study Start
February 1, 2015
Primary Completion
November 1, 2015
Study Completion
November 1, 2015
Last Updated
January 29, 2016
Record last verified: 2016-01
Data Sharing
- IPD Sharing
- Will not share